<DOC>
	<DOCNO>NCT00888004</DOCNO>
	<brief_summary>This study evaluate safety efficacy administration AFQ056 combination L-dopa , reduce number L-dopa related dyskinesia Parkinson 's disease patient .</brief_summary>
	<brief_title>Efficacy Safety AFQ056 Reducing L-dopa Induced Dyskinesias Parkinson 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Patients Parkinson 's Disease Patients Ldopa induce dyskinesia least 3 month Patients Ldopa treatment least 3 year , stable 1 month minimum History severe allergy food drug Very low high body weight . Prior surgery Parkinson 's Disease Smokers Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Parkinson 's</keyword>
	<keyword>L-dopa</keyword>
	<keyword>dyskinesia</keyword>
</DOC>